Global trial tests promising new drug combo for aggressive lung cancer
NCT ID NCT07226999
Summary
This study is testing a new medicine called PF-08634404 when given alongside standard chemotherapy for adults with extensive-stage small cell lung cancer, a fast-spreading type of lung cancer. The research has two parts: first checking safety, then comparing the new combination to an existing treatment to see which helps patients live longer. The trial aims to find better ways to control this aggressive disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Highlands Oncology Group
RECRUITINGSpringdale, Arkansas, 72762, United States
-
Kansai Medical University Hospital
RECRUITINGHirakata, Osaka, 573-1191, Japan
-
Mid Florida Hematology and Oncology Center
RECRUITINGOrange City, Florida, 32763, United States
-
Pan American Center for Oncology Trials, LLC
RECRUITINGSan Juan, Other, 00909, Puerto Rico
-
Texas Oncology - Gulf Coast
RECRUITINGWebster, Texas, 77598, United States
-
Texas Oncology - San Antonio
RECRUITINGSan Antonio, Texas, 78130, United States
Conditions
Explore the condition pages connected to this study.